13F Holdings
中文EN

LEGN Legend Biotech Corp IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1801198 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY64.0%
TTM net income YoY-67.7%
TTM EPS YoY-68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin61.4%
Operating margin—
Net margin-28.8%
FCF margin-12.5%
EBITDA margin—

Returns

ROE-29.1%
ROA-17.4%
ROIC (approx.)—
Asset turnover0.60x

Leverage & solvency

Liabilities / assets42.2%
Debt / equity0.32x
Current ratio1.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.03B$627.30M$285.10M$117.00M$68.83M
Cost of revenue$397.10M$216.40M$144.20M$65.36M$0
Gross profit$631.80M$410.90M$140.90M$51.64M$68.83M
R&D expense$414.70M$413.50M$382.20M$335.65M$313.35M
Operating income-$136.50M-$309.50M-$528.10M——
Interest expense$21.40M$21.60M$21.80M$10.80M$900,000
Pretax income-$282.60M-$158.10M-$520.20M-$445.72M-$407.20M
Income tax$14.20M$18.90M-$1.90M$625,000-$3.61M
Net income-$296.80M-$177.03M-$518.25M-$446.35M-$403.58M
EPS (basic)-0.81-0.48-1.47-1.40-1.43
EPS (diluted)-0.81-0.48-1.47-1.40-1.43
Weighted avg. shares (diluted)368.64M365.70M352.17M318.08M—
Balance sheet
Cash & equivalents$901.90M$286.70M$1.28B$786.00M$688.94M
Receivables$13.10M$6.40M$100.04M$90,000$50.41M
Inventory$32.00M$23.90M$19.43M$10.35M$1.75M
Current assets$1.25B$1.28B$1.50B$1.10B$949.85M
PP&E, netmay include right-of-use assets (IFRS)$116.30M$99.30M$108.80M$105.17M$102.51M
Intangibles$1.90M$2.20M$4.06M$3.41M$4.68M
Total assets$1.73B$1.67B$1.85B$1.33B$1.12B
Current liabilities$636.40M$277.70M$216.42M$297.79M$229.20M
Short-term debt$319.10M$0———
Long-term debt$0$301.20M$281.33M$260.93M$120.46M
Total debt$319.10M$301.20M$281.33M$260.93M$120.46M
Total liabilities$731.60M$629.60M$597.24M$586.65M$353.52M
Shareholders' equity$1.00B$1.04B$1.25B$744.31M$765.94M
Net debt-$582.80M$14.50M-$996.37M-$525.07M-$568.48M
Cash flow statement
Operating cash flow-$100.20M-$144.00M-$393.30M-$201.28M-$198.47M
Capital expenditure$28.60M$14.10M$20.10M$20.93M$42.20M
Free cash flow-$128.80M-$158.10M-$413.40M-$222.21M-$240.66M
Investing cash flow$709.60M-$850.60M$92.90M-$77.09M-$194.98M
Financing cash flow-$300,000$5.70M$791.40M$377.98M$626.66M
Stock-based compensation$64.60M$68.90M$47.70M$34.34M$20.16M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.